Clinical Study
Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases
Table 2
Results of hepatotoxicity and treatment with gefitinib and erlotinib.
| Case | Worst grade of gefitinib-induced hepatotoxicity | Peak AST/ALT levels by gefitinib-induced hepatotoxicity (mg/dL) | Time to gefitinib-induced hepatotoxicity (days) | Response by gefitinib | Duration of treatment with gefitinib (days) | Retreatment with gefitinib | Initial dose of erlotinib (mg) | Worst grade of erlotinib-induced hepatotoxicity | Peak AST/ALT levels by erlotinib-induced hepatotoxicity (mg/dL) | Response by erlotinib | Duration of treatment with erlotinib (days) |
| 1 | 2 | 63/155 | 22 | PR | 47 | decreaseda | 100 | 2 | 46/85 | PR | 159 | 2 | 3 | 159/280 | 175 | PR | 189 | decreaseda | 150 | 0 | 22/21 | SD | 92 | 3 | 2 | 128/197 | 42 | PR | 42 | no | 100 | 0 | 23/31 | SD | 184 | 4 | 3 | 89/263 | 53 | PR | 204 | decreaseda | 100 | 1 | 70/62 | SD | 116 | 5 | 3 | 426/533 | 55 | PR | 167 | decreaseda | 100 | 1 | 71/45 | SD | 360 | 6 | 3 | 252/252 | 191 | PR | 191 | no | 100 | 0 | 17/28 | SD | 56 | 7 | 3 | 231/342 | 35 | PR | 58 | decreaseda | 75 | 0 | 18/22 | PR | 304 | 8 | 2 | 62/113 | 50 | SD | 50 | no | 75 | 0 | 23/30 | SD | 412 |
|
|
Abbreviations: AST: aspartate aminotransferase; ALT: alanine aminotransferase; PR: partial response; SD: stable disease.
aRetreatment with decreased amount of gefitinib.
|